A/RES/70/181
Special session of the General Assembly on the world drug problem to be held in 2016
(b) The opening of the special session shall include statements by the
Secretary-General, the President of the General Assembly, the Chair of the
Commission on Narcotic Drugs, the Executive Director of the United Nations Office
on Drugs and Crime, the President of the International Narcotics Control Board and
the Director-General of the World Health Organization;
(c) The general debate shall include statements by the regional groups,
Member States, observer States and observers, relevant international organizations
and representatives of non-governmental organizations;
(d) Representatives of non-governmental organizations in consultative status
with the Economic and Social Council are invited to participate in the special
session in accordance with the rules of procedure and established practice of the
General Assembly;
(e) In accordance with the rules of procedure and practice developed for
other special sessions of the General Assembly, the President of the Assembly, in
consultation with the Commission on Narcotic Drugs, which will take into
consideration inputs from other relevant stakeholders, including civil society, shall
draw up a list of representatives of relevant non-governmental organizations,
representatives of civil society and the scientific community, academia, youth
groups and other relevant stakeholders that may participate in the special session,
with due regard to geographical balance;
(f) The Commission on Narcotic Drugs, as the entity leading the
preparations for the special session, shall address in an open-ended manner,
supported and guided by the President of the General Assembly, the organizational
arrangements, including chairing arrangements, speakers and participation, for the
following round tables, while considering the Political Declaration and Plan of
Action on International Cooperation towards an Integrated and Balanced Strategy to
Counter the World Drug Problem, 1 in line with Assembly resolutions 67/193 and
69/201:
Round table 1: Demand reduction and related measures, including prevention
and treatment, as well as health-related issues; and ensuring the availability of
controlled substances for medical and scientific purposes, while preventing
their diversion (“drugs and health”):
(i)
Demand reduction and related measures, including prevention and
treatment, as well as health-related issues, including HIV/AIDS prevention,
treatment and care;
(ii) Ensuring the availability of controlled substances for medical and
scientific purposes, while preventing their diversion;
Round table 2: Supply reduction and related measures; responses to drugrelated crime; and countering money-laundering and promoting judicial
cooperation (“drugs and crime”):
(i)
Domestic, regional and cross-regional responses to drug-related
crime; and countering money-laundering, including, where appropriate, in
connection with the financing of terrorism, and promoting judicial
cooperation in criminal matters;
(ii) Addressing emerging issues, including new psychoactive substances,
precursors and the misuse of the Internet;
2/4